Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems
- PMID: 24140545
- DOI: 10.1016/j.ijpharm.2013.10.019
Further experimentation of inhaled; LANTUS, ACTRAPID and HUMULIN with todays' production systems
Abstract
Background: Several aerosol production systems have been used for aerosol insulin production. However; since the first studies several new models of jet-nebulizers and ultrasound nebulizers have been introduced in the market.
Materials and methods: Three different models of jet-nebulizers (different brands, same properties) and three different ultrasound nebulizers (different brands, same properties). Six residual cups (2 small ≤ 6 ml and 3 large ≤ 8 ml) were used for the jet-nebulizers. The ultrasound nebulizers were used with their facemasks or with their inlets which were included in the purchase package.
Results: Ultrasound nebulizers; LANTUS produces by far the lowest mean droplets (2.44) half the size of the other two drugs (4.43=4.97). GIMA nebulizer is the most efficient producing one third of the droplet size of SHIMED and one second of EASYNEB (2.06<3.15<6.62). Finally, the 4 ml loading concentration is more suitable for supporting the production of smaller droplets (3.65<4.24). Drugs and nebulizers act interactively yielding very large droplets when ACTRAPID and HUMULIN are administered in joint with SHIMED nebulizer (9.59=7.72). Jet-nebulizers; HUMULIN again is the least preferred insulin since it hardly reaches the low but equal performance of others at the loading level of 6 ml. Residual cups E and B produce uniquely lower mean droplets at loading level 6.
Conclusions: Ultrasound nebulizers; the best suggested combination should be LANTUS insulin, GIMA nebulizer administered at loading dose of 4 ml jet-nebulizers. A global review can give the best combination: the lowest mean droplets are produced when the drugs LANTUS (mostly) and ACTRAPID are administered, applying the SUNMIST nebulizer in concert with residual cup B at loading levels of 6 ml.
Keywords: Actrapid (PubChem SID: 135350514); Aerosol insulin; Carboplatin (PubChem CID: 10339178); Cisplatin (PubChem CID: 84093); Docetaxel (PubChem CID: 148124); Doxorubicin (PubChem CID: 31703); Gemcitabine (PubChem CID: 60750); Humulin Regular (PubMed CID: 16129672); Jet-nebulizers; Lantus (PubChem CID: 44146714); Paclitaxel (PubChem CID: 36314); Tobramycin (PubChem CID: 36294); Ultrasound.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Experimentation with inhaled bronchodilators and corticosteroids.Int J Pharm. 2014 Jan 30;461(1-2):411-8. doi: 10.1016/j.ijpharm.2013.12.010. Epub 2013 Dec 17. Int J Pharm. 2014. PMID: 24361267
-
Internal mouthpiece designs as a future perspective for enhanced aerosol deposition. Comparative results for aerosol chemotherapy and aerosol antibiotics.Int J Pharm. 2013 Nov 18;456(2):325-31. doi: 10.1016/j.ijpharm.2013.09.004. Epub 2013 Sep 11. Int J Pharm. 2013. PMID: 24035789
-
New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.Int J Pharm. 2013 Oct 15;455(1-2):182-8. doi: 10.1016/j.ijpharm.2013.07.040. Epub 2013 Jul 23. Int J Pharm. 2013. PMID: 23891745
-
Design principles of liquid nebulization devices currently in use.Respir Care. 2002 Nov;47(11):1257-75; discussion 1275-8. Respir Care. 2002. PMID: 12425742 Review.
-
Formulations and nebulizer performance.Respir Care. 2002 Nov;47(11):1305-12; discussion 1312-3. Respir Care. 2002. PMID: 12425745 Review.
Cited by
-
Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination.J Cancer. 2018 Apr 30;9(11):1973-1977. doi: 10.7150/jca.24782. eCollection 2018. J Cancer. 2018. PMID: 29896282 Free PMC article.
-
Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From In vitro to In vivo.J Cancer. 2024 Jan 1;15(4):871-879. doi: 10.7150/jca.90732. eCollection 2024. J Cancer. 2024. PMID: 38230210 Free PMC article.
-
Inhaled chemotherapy adverse effects: mechanisms and protection methods.Lung Cancer Manag. 2020 Jan 16;8(4):LMT19. doi: 10.2217/lmt-2019-0007. Lung Cancer Manag. 2020. PMID: 31983927 Free PMC article. Review.
-
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.Drug Des Devel Ther. 2014 Oct 7;8:1753-63. doi: 10.2147/DDDT.S70277. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25336919 Free PMC article.
-
Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.J Thorac Dis. 2014 Oct;6(10):1411-9. doi: 10.3978/j.issn.2072-1439.2014.08.38. J Thorac Dis. 2014. PMID: 25364518 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources